The patients were assessed for definitive GEM efficacy, and were thus investigated for correlations between GEM sensitivity-related gene expression and clinical efficacy of GEM monotherapy. Clinicopahtologic data for the 35 patients are shown in Table 1. Evaluation of response to GEM by

imaging study was based on the Response Evaluation Criteria in Solid Tumors (RECIST). The GEM-effective patients were defined as having a partial response (PR) by imaging studies or as having stable disease (SD) by imaging studies and a 50% or more decrease in both of abnormal CA 19-9 and CEA titers in sera, as compared to pretreatment values. Table 1 Clinical characteristics of patients JPH203 cost receiving GEM monotherapy. Number of patients 35 Age (y) Mean ± SD (Range) 61.3 ± 8.5 (46–77) Gender Male:Female 16: 19 Location Head: Body/tail 7: 28 Follow-up time from commencement of GEM monotherapy (mo)   Median (Range) 7.7 (3.0–21.4) Number of courses of GEM

monotherapy   Mean ± SD (Range) 5.9 ± 4.0 (2–16) GEM efficacy Effective*: Non-effective 12: 23 GEM, gemcitabine *Effective, selleck partial response by imaging study or stable disease by imaging study with 50% or more decrease in tumor markers compared to pretreatment values This study was performed in accordance with the human and ethical principles of research set forth in the Helsinki guidelines. Informed consent was obtained from all patients who participated in the investigation. This study was approved by the institutional review boards of Osaka City University Graduate School of Medicine and Aichi Cancer Center. RNA isolation linear RNA polymerase amplification The extracted RNA from EUS-FNA sample was insufficient for FDA analysis; therefore, RNA were amplified as described elsewhere [10]. Briefly, the sample RNA was subjected to PRT062607 reverse transcription with T7 RNA polymerase-based linear amplification using the Agilent Low RNA Input Linear Amplification Kit (Agilent Technology, Inc.) to synthesize cDNA. The same kit was used for synthesized cDNA to amplify antisense RNA (aRNA) by in vitro transcription using T7 RNA polymerase. During this procedure, amplified aRNAs from the

sample 17-DMAG (Alvespimycin) HCl and the reference RNA (mix of RNAs from pancreatic cancer cell line BxPC-3 and colon cancer cell line DLD-1, 1:1 ratio) were labeled with Cyanine 5 (cy5) and Cyanine 3 (cy3) monofunctional reactive dyes (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), respectively. FDA analysis FDA included 133 genes that code sensitivity-related factors such as thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD), and molecular targets such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF). With regard to GEM sensitivity-related factors, dCK, hENT1, hENT2, deoxycytidylate deaminase (DCD), cytidine deaminase (CDA), 5′-nucleotidase (5′-NT), ribonucleotide reductase 1 (RRM1) and RRM2 were included on FDA.